8-K: Viant Technology Faces Nasdaq Non-Compliance After Director Resignation, Holds Annual Meeting

Viant Technology Inc. reported a director's resignation leading to a Nasdaq non-compliance notice, while also holding its annual meeting where directors were elected and the auditor was ratified.

Summary

• Viant Technology Inc. announced the resignation of Elizabeth Williams from its Board of Directors and Audit Committee, effective June 5, 2024.
• This resignation resulted in the company not meeting the Nasdaq requirement of having at least three independent directors on the Audit Committee.
• Nasdaq notified Viant on June 7, 2024, of this non-compliance, granting a cure period until the earlier of the 2025 annual meeting or June 5, 2025.
• The company intends to appoint a new independent director to regain compliance within the cure period.
• Viant held its 2024 annual meeting on June 4, 2024, with 91.3% of voting power present.
• Tim Vanderhook and Vivian Yang were elected as Class III directors, serving until the 2027 annual meeting.
• The selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.

Sentiment

Score: 4

Explanation: The document contains negative news regarding Nasdaq non-compliance, but also positive news about the annual meeting. The overall sentiment is slightly negative due to the compliance issue.

Positives

• The company has a cure period to regain compliance with Nasdaq listing rules.
• The annual meeting was successfully held with a high level of shareholder participation.
• The company has a plan to appoint a new independent director to the board and audit committee.

Negatives

• The resignation of a director led to a non-compliance notice from Nasdaq.
• The company's Audit Committee is temporarily not in compliance with Nasdaq listing rules.

Risks

• Failure to appoint a new independent director within the cure period could lead to further action from Nasdaq.
• The company's stock price could be negatively impacted by the non-compliance notice.
• There is a risk that the company may not be able to find a suitable independent director within the required timeframe.

Future Outlook

The company plans to appoint an additional independent director to its Board and the Audit Committee prior to the end of the cure period to regain compliance with Nasdaq listing rules.

Management Comments

• The company intends to appoint an additional independent director to its Board and the Audit Committee prior to the end of the cure period.

Industry Context

Director resignations and subsequent non-compliance notices are not uncommon in the corporate world, but they can raise concerns about governance and stability. Companies must act swiftly to address such issues to maintain investor confidence and regulatory compliance.

Comparison to Industry Standards

• The requirement for a minimum of three independent directors on the audit committee is a standard practice for companies listed on major exchanges like Nasdaq.
• Many companies have similar governance structures to ensure independent oversight and compliance.
• Failure to meet these standards can lead to delisting or other penalties, making it crucial for Viant to address the issue promptly.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the Nasdaq non-compliance and its potential impact on the stock price.
• The company's reputation could be affected by the non-compliance notice.
• Employees may be concerned about the stability of the company's governance.

Next Steps

• The company needs to appoint an additional independent director to its Board and the Audit Committee.
• The company must regain compliance with Nasdaq Listing Rule 5605(c)(2) before the end of the cure period.

Key Dates

Keywords

Nasdaq, Audit Committee, Director Resignation, Annual Meeting, Compliance, Independent Director, Deloitte & Touche, Corporate Governance